Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Deutsch
- Anmerkungen
-
Frankfurt am Main, Johann Wolfgang Goethe-Universität, Dissertation, 2025
- Schlagwort
-
Impfung
COVID-19
SARS-CoV-2
Impfstoff
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2025
- Urheber
- Beteiligte Personen und Organisationen
- DOI
-
10.21248/gups.89765
- URN
-
urn:nbn:de:hebis:30:3-897654
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ovčar, Eugen
- Hauser, Ingeborg A.
- Groot, Kirsten de
- Munschauer, Mathias
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2025
Ähnliche Objekte (12)
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Technetium abundance in Omicron Ceti
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Technetium abundance in Omicron Ceti
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Technetium abundance in Omicron Ceti
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants